PARSANEZHAD M, RAOOFI M, ALBORZI S, OMRANI G. A PROSPECTIV E, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF DEXAMETHASONE DURING THE FOLLICULAR PHASE IN CLOMIPHENE RESISTANT PATIENTS WITH POLYCYSTIC OVARY SYNDROME AND NORMAL DHEAS. Med J Islam Repub Iran 2003; 17 (3) :203-207
URL:
http://mjiri.iums.ac.ir/article-1-682-en.html
From the Division of Infertility and Reproductive Endocrinology, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz I.R. Iran. , parsame@sums.ac.ir
Abstract: (5304 Views)
In order to evaluate the effects of short course administration of dexamethasone
(DEX) combined with clomiphene citrate (CC) in CC-resistant patients with
polycystic ovary syndrome (PCaS) and normal DHEAS, a prospective, double
blind, placebo controlled, randomized study was undertaken at referral university
hospitals,
Two-hundred and thirty women with PCOS and normal DHEAS who failed
to ovulate with a routine protocol of CC received 200 mg of CC from day 5 to 9
and 2 mg of DEX from day 5 to 14 of the menstrual cycle. The control group
received the same protocol of CC combined with placebo.
Follicular development, hormonal status, ovulation rate, and pregnancy rate
were evaluated.
Mean follicular diameters were 18.4124±2.4314 mm and 13.8585±2.0722
mm (p<0.001) for treatment and placebo group respectively. Eighty-eight percent
of treatment and 20% of the control group had evidence of ovulation. The difference
of cumulative pregnancy rate in treatment and control groups was statistically
significant (p<0.000l).
Hormonal levels, follicular development and cumulative pregnancy rate improved
with the addition of DEX to CC in CC-resistant patients with PCOS and
normal DHEAS.This regimen is recommended before any gonadotropin therapy
or surgical intervention.